The blind spot in the nicotine replacement therapy literature: assessment of the double-blind in clinical trials.
While clinical trials of medications often use a double-blind procedure, the integrity of the blind and its relationship to treatment outcome is seldom examined. In this review, 73 double-blind, placebo-controlled clinical trials of the nicotine replacement therapies (NRTs) in smoking cessation were identified. Seventeen articles were found that assessed blindness integrity, demonstrating major variations in the assessment, analysis, and reporting of blindness integrity. Although 12 studies found that subjects accurately judged treatment assignment at a rate significantly above chance, the available literature does not permit definitive conclusions about blindness integrity. Recommendations for the assessment, analysis, and reporting of blindness integrity are made.
Mooney
Marc
M
Tobacco Use Research Center, University of Minnesota, 2701 University Avenue S.E., Suite 201, Minneapolis, MN 55414, USA. Marc.E.Mooney@uth.tmc.edu
White
Thom
T
Hatsukami
Dorothy
D
D018849:Controlled Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D009538:Nicotine / Q000627:therapeutic use*; D018722:Nicotinic Agonists / Q000627:therapeutic use*; D016540:Smoking Cessation / Q000379:methods*
D018722:Nicotinic Agonists; D009538:Nicotine